Skip to main content
. 2023 Sep 6;8(10):1263–1282. doi: 10.1016/j.jacbts.2023.06.006

Figure 1.

Figure 1

Changes in Cardiac NMT2 Expression in Heart Failure of Mice and Humans

(A) Immunoblot analysis of N-myristoyltransferase 1 (NMT1) and N-myristoyltransferase 2 (NMT2) in the murine heart. Wild-type mice were subjected to either sham procedure or transverse aortic constriction (TAC) surgery using a 28-gauge blunt needle and analyzed 4 weeks after the operation. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as the loading control. The densitometric analysis is shown in the graphs (n = 5 in each). (B) Immunohistochemistry for NMT1 (brown) and NMT2 (brown) in paraffin-embedded sections from mouse hearts. Scale bars = 20 μm. (C) Quantitative analysis of the ratios of NMT1- or NMT2-positive cardiomyocytes determined by immunohistochemistry (n = 3 and 4, respectively). (D) Immunohistochemical analysis of NMT1 (brown) and NMT2 (brown) in paraffin-embedded heart section from non–heart failure control subjects and heart failure patients with idiopathic dilated cardiomyopathy. Scale bars = 20 μm. (E) Quantitative analysis of the ratios of NMT1- or NMT2-positive cardiomyocytes by immunohistochemistry (n = 6 and 12, respectively). All data are presented as mean ± SEM. ∗∗P < 0.01 and ∗∗∗P < 0.001 by the unpaired Student’s t-test (2-sided).